H35.17
Retrolental fibroplasia
Clinical Classification Guidelines
Medical Intelligence & Overview
Retrolental fibroplasia, also known as retinopathy of prematurity, is a condition that affects the eyes of premature infants. It involves abnormal development of blood vessels in the retina, which can lead to vision impairment or loss if not properly managed. This condition primarily occurs in infants born prematurely or with low birth weights, often during the early weeks of life. Understanding retrolental fibroplasia is important for caregivers, as early detection and treatment can significantly improve outcomes.
Causes & Symptoms
Clinical Causes: Premature birth: Infants born before completing the normal gestational period are at increased risk. Low birth weight: Babies weighing less than 3.3 pounds (1500 grams) are more susceptible. Oxygen therapy: High levels and prolonged exposure to supplemental oxygen in neonatal intensive care units can contribute to abnormal blood vessel growth. Genetic factors: A family history of eye problems may slightly increase risk. Breathing disorders: Conditions like respiratory distress syndrome can be associated with treatment factors influencing the development of the disease.
Key Symptoms: No symptoms in early stages, with the condition often detected during routine eye screenings. Leukocoria: A white reflection from the retina, sometimes noticed in photographs. Strabismus: Crossed or misaligned eyes due to visual impairment. Poor vision or vision loss as the disease progresses. Nystagmus: Involuntary eye movements in advanced cases. Potential retinal detachment if the condition worsens without intervention.
Diagnostic & Treatment
Diagnosis Path: Diagnosis involves comprehensive eye examinations conducted by a pediatric ophthalmologist. The exam typically includes dilated retinal examinations to evaluate blood vessel development and identify abnormal growth or scarring. Retinal imaging or fluorescein angiography may be used for detailed assessment. Screening is crucial for infants at risk, usually starting around 4-6 weeks after birth or earlier if the infant is very premature.
Treatment Protocols: Treatment focuses on halting abnormal blood vessel growth and preventing retinal scarring or detachment. Common approaches include: - Laser therapy: Precisely targeted laser burns are applied to areas of abnormal blood vessels to inhibit further growth. - Cryotherapy: Used in some cases to destroy abnormal vessels when laser therapy isn't feasible. - Ongoing monitoring: Regular eye examinations to track disease progression. Advances in neonatal care, such as controlled oxygen levels, have reduced the incidence of retrolental fibroplasia. Early intervention is key to preserving vision and preventing long-term complications.
Clinical Advice & FAQs
Billing Guidance
Is H35.17 a billable ICD-10 code?
Yes, H35.17 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report H35.17?
Clinical documentation must specify the nature of Retrolental fibroplasia and any associated comorbidities for accurate reporting.
Cite this Clinical Reference